Pangaea Oncology (XMAD:PANG) Other Net Income (Loss) : €-0.02 Mil (TTM As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Pangaea Oncology Other Net Income (Loss)?

Pangaea Oncology's Other Net Income (Loss) for the six months ended in Jun. 2024 was €-0.18 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.02 Mil.

Pangaea Oncology's quarterly Other Net Income (Loss) increased from Jun. 2023 (€-0.16 Mil) to Dec. 2023 (€0.16 Mil) but then declined from Dec. 2023 (€0.16 Mil) to Jun. 2024 (€-0.18 Mil).

Pangaea Oncology's annual Other Net Income (Loss) increased from Dec. 2021 (€-0.00 Mil) to Dec. 2022 (€-0.00 Mil) and increased from Dec. 2022 (€-0.00 Mil) to Dec. 2023 (€0.00 Mil).

Pangaea Oncology Other Net Income (Loss) Historical Data

The historical data trend for Pangaea Oncology's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pangaea Oncology Other Net Income (Loss) Chart

Pangaea Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Pangaea Oncology Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-0.16	0.16	-0.18

Pangaea Oncology Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.02 Mil.

Pangaea Oncology Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Pangaea Oncology's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Pangaea Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Pangaea Oncology SA (XMAD:PANG) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Calle Sabino Arana, 5-19, Barcelona, ESP, 08028

Website

http://www.panoncology.com

Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.

Pangaea Oncology Headlines

No Headlines